Miracor : a positive follow-on financing for an interventional cardiology start-up active in a massive market
Miracor Medical SA is a medical device company developing disruptive solutions to treat severe heart diseases. The company was founded in 2008 by Professor Dr. Dr. Werner Mohl and the European venture capital firms Earlybird and Delta Partners.
Miracor develops the PiCSO (Pressure-controlled Intermittent Coronary Sinus Occlusion) Impulse System, a technology platform designed to improve clinical outcome of patients with impaired cardiac function. The PiCSO Therapy seeks to increase blood flow to the affected heart tissue, thereby improving the overall heart function after an Acute Myocardial Infarction (AMI). Recent Clinical Studies have successfully demonstrated the positive effects of PiCSO on myocardial function and infarct size in acute heart attack patients. The PiCSO Impulse System consists of a driving console and associated catheters and offers the Heart Team new options to improve clinical outcome in Acute Myocardial Infarction patients. The market of AMI that Miracor is active in is pretty much untapped and is estimated to be between 6 and 10 billion EUROs on annual basis.
Early 2018 the company announced a series-D 25M€ financing round, in connection to which the company relocated to Belgium, supported by the Wallonia government and some public Belgian investors.
The objectives of this presentation will be to give a short overview of Miracor Medical, and to explain the recent financing, how the Belgian medtech ecosystem supported Miracor, and Miracor’s forward-looking plans.